Ratings Simulations Plus, Inc.

Equities

SLP

US8292141053

Real-time Estimate Cboe BZX Other stock markets 03:22:12 2024-04-29 pm EDT			5-day change	1st Jan Change
45.28 ^USD	+1.32%		+0.13%	+0.69%

Apr. 17	InnoGI Technologies and Simulations Plus Combine Forces to Offer Next-Level Modeling Solutions for the Prediction of Oral Drug Performance	CI
Apr. 04	Sector Update: Health Care Stocks Slump Late Afternoon	MT

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Analysts covering this company mostly recommend stock overweighting or purchase.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

With an expected P/E ratio at 68.06 and 55.52 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SIMULATIONS PLUS, INC.	+0.69%	893M		C
VEEVA SYSTEMS INC.	+4.73%	32.47B		C
PRO MEDICUS LIMITED	+16.51%	7.45B		C-
SECTRA AB	+23.49%	3.89B		B-
EVOLENT HEALTH, INC.	-15.70%	3.17B		C-
OMNICELL, INC.	-27.45%	1.28B		B
LUNIT INC.	-33.58%	1.09B		-
B-SOFT CO.,LTD.	-33.74%	902M		-
VERADIGM INC.	-25.64%	857M	-	C+
SURGICAL SCIENCE SWEDEN AB	-14.74%	693M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes